Traditional Chinese medicine (TCM) is a well-accepted therapy for atopic dermatitis (AD). However, there are currently no evidence-based guidelines integrating TCM and Western medicine for the treatment of AD, limiting the clinical application of such combined approaches. Therefore, the China Association of Chinese Medicine initiated the development of the current guideline, focusing on key issues related to the use of TCM in the treatment of AD. This guideline was developed in accordance with the principles of the guideline formulation manual published by the World Health Organization. A comprehensive review of the literature on the combined use of TCM and Western medicine to treat AD was conducted. The findings were extensively discussed by experts in dermatology and pharmacy with expertise in both TCM and Western medicine. This guideline comprises 23 recommendations across seven major areas, including TCM syndrome differentiation and classification of AD, principles and application scenarios of TCM combined with Western medicine for treating AD, outcome indicators for evaluating clinical efficacy of AD treatment, integration of TCM pattern classification and Western medicine across disease stages, daily management of AD, the use of internal TCM therapies and proprietary Chinese medicines, and TCM external treatments. Please cite this article as: Du XR, Wu MY, Tao MC, Lin Y, Gu CY, Wu MF, Cao Y, Chen DC, Li W, Wang HW, Wang Y, Wang Y, Lu HZ, Liu X, Su XF, Li FL. Clinical practice guidelines for the diagnosis and treatment of atopic dermatitis with integrative traditional Chinese and Western medicine. J Integr Med. 2025; 23(6):641-653.
Dermatitis, Atopic/drug therapy* ; Humans ; Medicine, Chinese Traditional/methods* ; Integrative Medicine ; Drugs, Chinese Herbal/therapeutic use* ; Practice Guidelines as Topic

objective:To analyze the contributed papers and publications in the first half year of 2020 from Shanghai Journal of Preventive Medicine， especially the COVID-19 papers， to provide basis for the academic journals to win out during the public hot points. Methods:All the papers contributed in the first half year of 2020 from Shanghai Journal of Preventive Medicine， were collected to analyze the sources parameters， editing parameters. All published papers were collected to analyze the sources parameters， editing parameters and their usages （downloads and citations）. Results:There were 450 papers contributed in the first half year of 2020， 129 papers were accepted accounting for 28.67%. Among them， 116 papers were COVID-19 papers accounting for 25.78%， and 32 papers were accepted accounting for 24.81%. the March was the highest month of contribution， also for COVID-19 papers. Many academic domains such as infectious disease， women and children health， clinic science， chronic disease， social medicine， public hygiene and others were predominated among those papers. COVID-19 papers dominated in domains of infectious disease and social medicine. According to the non-COVID-19 papers， the COVID-19 papers had higher numbers of peer reviewers， lower days for back improvement， lower days for refusals or acceptance， also had lower copy percentages by plagiarism check （all P<0.05）. there were 106 papers published in the first half year of 2020. Published COVID-19 papers had higher number of authors， higher numbers of references in term of governments reports， foreign references and less than 5 years references （all P<0.05）. Those published COVID-19 papers had better usages than those no-COVID-19 papers， adjusted downloads were 2 077.37/year vs 111.53/year， adjusted citations were 12.99/year vs 0.49/year. It was obvious that the published COVID-19 papers had very excellent social influences and academic influences （P<0.001）. Conclusion:Publication in the first half year of 2020 from Shanghai Journal of Preventive Medicine is high-qualified and is good for the journal’s improvement in social influences and academic influences. It is important for academic journals to pay more attention to the hot points of public health accordingly.